SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Food - Processing and Agriculture >

Plandai Biotechnology, Inc. (PLPL)

Add PLPL Price Alert      Hide Sticky   Hide Intro
Moderator: captainscotty, F.STOTLER
Search This Board: 
Last Post: 4/27/2017 9:29:00 AM - Followers: 178 - Board type: Free - Posts Today: 0


Plandai Biotechnology South Africa (pty) Ltd, recently acquired by Protext Mobility, Inc, is publicly traded on the OTC Markets under the ticker symbol "TXTM"

The Company is actively engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Our initial product, Phytofare® Catechin Complex, has been clinically proven to have 10 times greater bioavailability over generic catechin extracts. Commencing early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in regulating blood sugar levels in diabetics. The trial will be conducted in the island country of Mauritius which has the highest per capita incidence of diabetes in the world. Assuming a favorable result, we anticipate having a product market ready by the end of 2017 and eventually filing for product claims with the US Food and Drug Administration.

We are majority-owned by Plandaí Biotechnology, Inc. (OTCQB: PLPL), a London-based holding company that controls over 8,000 acres of tea estate in the province of Mpumalanga, South Africa, and owns a 100,000 square foot manufacturing facility that produces Phytofare®.

PROTEXT MOBILITY CLOSES ACQUISTION OF PLANDAI BIOTECHNOLOGY WHOLLY OWNED SUBSIDIARY (PLPL-SA) Boca Raton, FL – January 11th, 2016 - Protext Mobility Inc. (OTCPINK: TXTM) announced that it has completed the acquisition of Plandaí Biotechnology South Africa (PTY) LTD “Plandaí SA”, a wholly owned subsidiary of Plandaí Biotechnology, Inc., publicly traded under the ticker (PLPL). Plandaí SA is a biotechnology firm engaged in the research and development of botanical extracts, such as green tea, aimed at treating metabolic disorders, including diabetes. The parent company of Plandaí SA, Plandaí Biotechnology, Inc., is the culmination of over 10 years of research and development in the field of plant extracts with principle holdings including raw materials processing, infrastructure, production facilities, farms and land totaling 7500 acres in the province of Mpumalanga, South Africa. Plandaí SA was established in 2014 by parent company, Plandaí Biotechnology, Inc. to provide a platform for expanding the research of Plandaí’s proprietary Phytofare® extracts into pharmaceutical applications. Phytofare® has been clinically proven in studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the parent company, Plandaí Biotechnology, focuses on selling Phytofare® as an ingredient to manufacturers in the nutraceutical industry, Plandaí SA will target the pharmaceutical market with a finished product. Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready in the latter half of 2017. David Lewis, Director of Protext Mobility, commented, “We’re pleased to announce this share exchange with Plandaí SA and we’re confident that this transaction will create exciting new opportunities for the company. Plandaí has a proven track record for delivering high-quality, science-based botanical ingredients that fit perfectly into the bio-pharmaceutical space. With the first human clinical trial set to commence in the first quarter of 2017, we anticipate great things in the coming months.” The Company is also pleased to announce the appointment of Mr. Roger Duffield to the role of Chief Executive Officer and Chairman of the Board. Mr Duffield is a seasoned executive, responsible for the massive undertaking and successful development of the 7500 acre Senteeko Estate. Mr.Duffield, is a hands on CEO, currently in South Africa, overseeing the 100,000 square foot factory, and preparing for the upcoming human clinical trial being conducted by Plandai SA. 


Movie by Plandai:

Interview of CEO (Audio / February 14, 2012)


Security Details


Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.

  A/S :        500 million confirmed / State of Nevada
  O/S :                              134.300.000 (Febr. 6th, 2015)
                                        160.520.000 (Oct. 1st, 2015
Free Float:                     66.300.000 (Febr. 6th, 2015)
                                  ? in oct. 2015

Incorporated in: NV,USA - Year of Inc.:  2012

                                                                                                                                                                                                                   Transfer Agent

Signature Stock Transfer, Inc., Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093, 972-612-4120

JUNE 29, 2015
Plandai Biotechnology Enters Into Agreement to Supply Phytofare to United Kingdom Distributor With First Purchase Order

GOODYEAR, AZ--(Marketwired - June 29, 2015) - Plandaí Biotechnology, Inc. (PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable green tea extract, Phytofare® Catechin Complex, today announced that it has entered into an agreement with ProTec Nutra (“ProTec”), a leading supplier of high quality ingredients to the European food and nutraceutical industry, to become the official distributor of the Company’s Phytofare® Catechin Complex in the United Kingdom (UK). ProTec has placed its first order for Plandaí’s Phytofare® Catechin Complex to fill confirmed orders that ProTec has received from its client base in the UK.

ProTec sources, develops and markets specialty ingredients and bulk products into the Functional Foods and Nutraceuticals markets in Europe with a number of manufacturing partners including Plandaí Biotechnology:

Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí, said, “Having a distributor with an ethos of quality and the customer base that ProTec does, shows our intention to supply our products to companies that specialize in high quality, branded ingredients. This also reaffirms our aim to become THE supplier of highly bioavailable extracts in the marketplace. ProTec has shown a complete understanding of what we’re bringing to the market and has managed to translate this into immediate sales in the United Kingdom. I fully expect sales to increase exponentially in the coming months due to their tireless work to promote only the highest quality ingredients.”

Gary Parker is the Sales Manager for ProTec Nutra and when commenting on what separates Plandaí’s Phytofare® from other green tea extracts he said, “ProTec Nutra is committed to looking for new and innovative nutritional ingredients. A Green Tea that is ‘so different’ to the Green Tea currently dominating the health food industry is a revelation. Phytofare® quite simply ‘ticks all the boxes.’ It’s actually ‘green,’ it’s not from China, it’s backed by clinical studies and with 10x the bioavailability of a generic Green Tea, the consumer gets a product that really works and the ‘cost per dose’ is significantly lower. Beat that!”

ProTec Nutra is part of the London Pharma & Chemicals Group, Ltd. (LPC) companies (, a privately owned group with over 30 years of experience and offices in eight countries. LPC specializes in the supply, promotion and distribution of specialty ingredients and pharmaceutical products.

Plandai Biotechnology, Inc. Signs Agreement to Become Exclusive Supplier to USN

LOGAN, UT--(Marketwired - May 11, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today announced its entry into an exclusive 3 year supply agreement with USN Worldwide. Pursuant to the contract, the Company will initially sell to USN commercial amounts of Phytofare® catechin complex for USN’S South African markets. Ultimately, the parties intend to expand USN’s purchases globally into other territories in which USN operates.

USN ( was founded in South Africa in 2000, and it remains a comprehensive health and nutrition supplement brand, driving the forefront of sports nutrition globally. Rapid expansion and an increasing consumer base have been realized through a commitment to leading product innovation, the highest quality raw material suppliers globally, premium manufacturing facilities and excellent customer support on all levels. All products are formulated with the backing of extensive research and scientific findings, as well as the important clinical trials to ensure efficacy and safety. USN continues its global growth strategy, and it is now being sold in pharmacies, FMCG and specialist retailers in over 53 countries on four continents.

This agreement also allows USN to further control the input costs around production, while enhancing product efficacy by replacing the generic green tea extracts in its extensive stable of innovative and market leading products, with the clinically proven highly bioavailable Phytofare® catechin complex. This agreement gives Plandai the opportunity to cement its relationship with a long-term global customer who has a vision for growth and market expansion.

Callum Baylis-Duffield, Vice President of Sales and Marketing for Plandaí, commented, “We are extremely pleased to enter into this agreement with a company that has the remarkable reputation of USN. As a leader in sports nutrition, they understand the benefits of phyto-availability within their product line-up, as well as the need to ensure that customers are getting the maximum potential and benefit from their supplements. Such a brand can only continue its innovative streak and fantastic track record.”

Irma Botes, Head of Research and Development at USN, added, “Establishing long-term relationships with a supplier like Plandaí is an important part of ensuring that we remain at the forefront of our industry. Customers are demanding more and more from their bodies and from their nutrition supplement partner, and USN remains committed to providing the best products to the global market place. Phytofare®, by focusing on both absorption and residence in the body, using all natural botanicals, gives us a huge competitive advantage -- an advantage we’re confident our customers will notice in their performance and overall health.”

USN Founder and CEO, Albe Geldenhuys commented, "Our industry is continually progressing with respect to product innovation and scientific findings. Establishing long-term relationships with leading suppliers globally ensures that our brand embraces the innovation and the science that drives this industry, cementing our position as a global leader. This agreement is a commitment to a mutual investment that will see further product improvements in our offering this year and well into the future."

   Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015____________________________________

NEW YORK, NY--(Marketwired - January 09, 2015) - Plandaí Biotechnology (PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with Plandaí's Chief Executive Officer, Roger Duffield, to discuss Plandaí's plans for 2015.

SMMG: First and foremost, can we get your reaction to the opening of your new production facility in South Africa and what does its completion mean for Plandaí in 2015?

Roger Duffield: "Well, opening the Senteeko facility is really the culmination of over a decade of research, sacrifice, and determination. Taking the initial concept that we could produce a highly bioavailable plant extract -- at a time when no one was even looking at the importance of bioavailability for nutraceuticals -- and then seeing it through to this point, has been an amazing journey that wouldn't have happened without the help and support of countless people. I get chills every time I visit Senteeko, drive thirty minutes on logging roads through thick forests, and then pass the gates to our estate and see the vast acres of tea with this amazing jewel of a factory sitting in the middle. I'm overwhelmed, excited, relieved, and deeply humbled all at the same time." 

SMMG: What is the significance of Plandaí's shift from a research and development company to a biotech that produces and sells products?

Roger Duffield: "Let me answer by first stating that Plandaí will always be a research and development company. When you look at the pharmacopeia of medicinal plants, you can see that there are hundreds of potential future research products for us. And even with just green tea catechins, we could spend a lifetime just on different human clinical trials as we explore the vast potential of this amazing plant.

"But, from a practical standpoint, now that the factory is opened, we can start generating revenues and positive cash flows. This will allow us to operate without dilution or incurring additional debt, expand our products lines, and return value to our shareholders. "Operationally, it means that we now have a whole new business model with new logistics. When you stop to think about what it takes to sell a product like Phytofare®, it requires so many moving parts working in harmony. Growing the leaf, picking it properly, manufacturing, batch testing, packaging, tracking and quality control, shipping, customs. Then you have the sales aspect, which includes marketing, trade shows, literature. It's really quite a process that I think few people fully understand."

SMMG: In 2013 Plandaí announced its entrance into the cannabis research arena, in 2014, the company secured a licensing agreement with Diego Pellicer and then obtained a consent letter from the Minister of Health in Uruguay to begin growing cannabis and producing an extract for animal testing, so what can we expect in 2015?

Roger Duffield: "Our plan at this point is to establish the cannabis growing infrastructure in Uruguay this year with an expectation of having an extract ready for testing six to nine months after it comes online. Our initial goal of having a product market-ready by the end of 2014 proved unrealistic once we determined that current U.S. laws, even in states where marijuana is legalized, prohibited us from legally acquiring cannabis, producing an extract, and then testing it inside the U.S. "Our operation in Uruguay will allow us to better control the chemical profile and then conduct our research into various neural disorders in a safe, legal, and scientifically validated manner. Also, we will be able to establish standards for dosage and chemical profile, which has so far been very limited with respect to cannabis research."

SMMG: After releasing the data in 2014 from a human clinical trial performed at North West University in South Africa that showed Plandaí's Phytofare® Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract, what is next in the on-going research at North West University?

Roger Duffield: "Starting this month, the research team at North West University in South Africa, under the supervision of the Dean's office of the Faculty of Health Sciences and the inventor of the Pheroid® delivery system, Prof. Anne Grobler, will complete the third arm of the bioavailability study. This final phase will use the same 26 human subjects, but this time the study will incorporate the addition of Pheroid® to the Phytofare® extract. "We anticipate that adding the Pheroid® delivery system will increase the overall bioavailability while also opening up the potential to use our extracts in less controlled applications such as adding Phytofare® to other ingredients including topical creams and liquids, and in environments where you are less able to control exposure to outside influences such as UV light, which kills the antioxidants."North West University will also be conducting our human weight loss clinical trial, which will test the Phytofare® versus a placebo over 90 days and involving 120 patients. This trial will also be looking at a complete blood panel so we can identify from a medical standpoint the effects of catechins on everything from blood sugar to cholesterol. The results could potentially open entirely new fields of research."

SMMG: Any closing thoughts?

Roger Duffield: "2015 promises to be a productive year for Plandaí. With the completion of the new laboratory inside the Senteeko facility, we plan to produce our first citrus extract and then test its bioavailability followed by a human clinical trial to confirm improved respiratory benefits including symptom relief for sinus, colds and the flu. And, as always, we continue to explore the medical potential of other phytonutrients and expect to test new extracts throughout the year."


For press releases please visit:


                                                                                                                                                    PLANDAI BIOTECHNOLOGY at Africa                                                 





                                                                                                              Management Team
Roger Duffield President, Chief Executive officer and member of the Board of Directors

Callum Baylis-Duffield Vice-President and Global Director: Marketing Sales

David Rzepnicki Chief Financial Officer and member of the Board of Directors

Tim Matula Investor Relations and member of the Board of Directors

Roger Duffield
Chief Executive Officer
Plandai Biotechnology, Inc.
1451 North 200 East, Suite 130C
Logan, UT 9810

(Validity unkown:
Corporate Headquarters Address: 2226 Eastlake Ave E, #156 Seattle, Washington, 98102, USA
Phone: (425) 466-0212


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PLPL News: Plandai Biotechnology Gains Credibility with NutriBullet Deal 04/26/2017 09:00:00 AM
PLPL News: Amended Statement of Ownership (sc 13g/a) 04/24/2017 02:58:35 PM
PLPL News: Plandai Biotechnology Sets Aggressive Agenda for 2017 04/19/2017 08:34:00 AM
PLPL News: Amended Statement of Ownership (sc 13g/a) 02/01/2017 06:05:53 AM
PLPL News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 01/31/2017 04:18:04 PM
#13106  Sticky Note NEWS OUT TXTM (03/27/2017): Protext Mobility F.STOTLER 03/27/17 08:47:13 AM
#12965  Sticky Note Plandai Biotechnology South Africa (pty) Ltd, recently acquired captainscotty 01/31/17 04:49:12 PM
#13153   ...I forgot to add: I am here also Aston Martin 04/27/17 09:29:00 AM
#13152   Because the development of penny plays to scams Aston Martin 04/26/17 03:41:00 PM
#13151   Then move on. Really, why be here if mlh1979 04/26/17 12:59:35 PM
#13150   .. but 260.000.000 shares outstanding meanwhile(wrong shown here Aston Martin 04/24/17 12:52:32 PM
#13149   NutriBullets SuperFood Boost Featuring Plandai Biotechnology's Phytofare Expe cameron86 04/24/17 09:42:20 AM
#13148   BIG break of .03 coming!! cameron86 04/24/17 09:34:31 AM
#13147   Should be testing .03 here soon maybe today. cameron86 04/21/17 12:31:42 PM
#13146   Well, if you are right you are Aston Martin 04/21/17 11:26:50 AM
#13145   10% of 10,000 is 1,000 not 20 dollars???? cameron86 04/20/17 09:47:27 PM
#13144   Oh, +0.002 ... An 'investment' of $ 10000 Aston Martin 04/20/17 03:16:18 PM
#13143   Breakout............... Now we are thrilled already by +4% Aston Martin 04/20/17 02:53:27 PM
#13142   Nice breakout happen here and no ones around??? cameron86 04/20/17 12:23:19 PM
#13141   Who shall be impressed by this news? The Aston Martin 04/19/17 04:19:20 AM
#13140   Callum Duffield's latest altitudy 04/17/17 12:48:54 PM
#13139   Just broke second resistance, will be taking profits. sicric 04/12/17 12:21:38 PM
#13138   Sage advice, I seldom hold any stock anyway. sicric 04/12/17 12:00:52 PM
#13137   not worth it anymore in this stage Aston Martin 04/12/17 11:51:26 AM
#13136   I was talking a best short-term..., worked for me. sicric 04/12/17 11:02:52 AM
#13135   A 'sleeper' penny stock which never have seen Aston Martin 04/11/17 10:22:06 AM
#13134   It was a sleeper when I first bought sicric 04/10/17 01:55:31 PM
#13133   this stock is as dead as dead can Aston Martin 04/10/17 11:13:25 AM
#13132   EXACTLY !!!! How much more is needed to Aston Martin 04/10/17 11:11:14 AM
#13131   and dance naked in the flames throwing worthless tmonkey 04/10/17 10:41:32 AM
#13130   the duffields loyality is to their bank balanse!!!-they tmonkey 04/10/17 10:35:13 AM
#13129   the duffields loyality is to their bank balanse!!!-they tmonkey 04/10/17 10:35:06 AM
#13128   The Duffields' loyalty is to the Senteeko Tea altitudy 04/09/17 11:17:41 AM
#13127   #PLPL:Could be...Hopefully a surprise coming..:-} captainscotty 04/08/17 05:54:14 PM
#13126   Death by stock swindle - as always. By Aston Martin 04/08/17 03:39:40 PM
#13125   Volume before price !!! Majk76 04/07/17 03:53:24 PM
#13124   tripps soon???-the deal with the dead shell was tmonkey 04/07/17 02:45:46 PM
#13123   all-time-low ... thank you Duffield from a long Aston Martin 04/07/17 01:35:46 PM
#13122   You are right, shareholder are surprised that even Aston Martin 04/05/17 11:51:21 AM
#13121   #PLPL: Could one day surprise us all. captainscotty 04/04/17 07:03:02 PM
#13120   As long as you can still make jokes Aston Martin 04/04/17 04:29:00 PM
#13119   #PLPL: Glad I could put a smile captainscotty 04/03/17 05:57:51 PM
#13118   Good joke after all ! Aston Martin 04/03/17 05:41:56 PM
#13117   #PLPL: Ready for the big move north...:-) captainscotty 04/03/17 04:32:23 PM
#13116 GregLechuga 03/31/17 04:47:52 AM
#13115   I now believe the Nutri-Bullet product is PLPL, altitudy 03/29/17 06:12:39 PM
#13114   FYI TXTM Protext Mobility altitudy 03/29/17 11:08:11 AM
#13113   Things could look up for PLPL if TXTM altitudy 03/29/17 10:28:25 AM
#13112 ... click that at TXTM board and Aston Martin 03/29/17 08:04:39 AM
#13111   Yes, I am in since 2012 with 190.000 Aston Martin 03/29/17 08:02:03 AM
#13110   Yes ;-) ... nothing to say anymore about Aston Martin 03/29/17 08:00:21 AM
#13109   Did anyone in PLPL get any dividends?? Jmark601 03/27/17 05:51:50 PM
#13108   You don't beat around the bush, you come altitudy 03/27/17 05:39:42 PM
#13107   Aston Martin 03/27/17 01:30:47 PM
#13106   NEWS OUT TXTM (03/27/2017): Protext Mobility F.STOTLER 03/27/17 08:47:13 AM
#13105   Thank you for your kind posts - may Aston Martin 03/26/17 08:48:47 AM
#13104   Aston, I agree with your cynicism, and that altitudy 03/25/17 02:13:06 PM